Allergy Therapeutics (LON:AGY) Announces Quarterly Earnings Results

Allergy Therapeutics (LON:AGY) announced its quarterly earnings results on Monday. The company reported GBX (0.23) ($0.00) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a negative net margin of 72.86% and a negative return on equity of 266.59%.

Allergy Therapeutics Trading Down 1.6 %

LON:AGY opened at GBX 6.20 ($0.08) on Tuesday. The company has a market cap of £304.73 million, a PE ratio of -5.98, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. The company has a current ratio of 1.63, a quick ratio of 1.48 and a debt-to-equity ratio of 835.48. The company has a 50 day simple moving average of GBX 6.60 and a two-hundred day simple moving average of GBX 5.91. Allergy Therapeutics has a 12 month low of GBX 2.65 ($0.03) and a 12 month high of GBX 8 ($0.10).

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.